Aerie Pharmaceuticals reported a net loss of $85.4 million, or $1.96 per share, in the third quarter of 2018 compared with a net loss of $32.4 million, or $0.89 per share, in 2017’s third quarter, according to a press release.
Net product revenues for the quarter totaled $7.3 million from sales of Rhopressa (netarsudil ophthalmic solution 0.02%), which was launched in April.
The company’s selling, general and administrative costs increased from $19.8 million in 2017’s third quarter to $39.9 million this year, while research and development costs increased from $12.4 (Read more...)
Uncategorized